Novartis and Arrowhead Pharmaceuticals announced a landmark $200 million upfront licensing and collaboration deal focusing on Arrowhead’s preclinical small interfering RNA (siRNA) candidate ARO-SNCA for Parkinson’s disease. The partnership leverages Arrowhead’s Targeted RNAi Molecule (TRiM) platform, designed for non-invasive CNS delivery, aiming to silence alpha-synuclein, a key pathologic protein in Parkinson’s. Novartis gains global rights excluding China, advancing discovery-stage programs with a shared commitment to addressing neurodegenerative disorders.